Spin off companies

Although this is by no means expected from ICREA researchers, it so happens that sometimes they hit on something that shows promise of becoming a powerful new technology, but it seems impossible to develop that further without significant investment of time and money. In these cases, many choose to explore the option of creating a spin-off company dedicated to the concept.

List of spin off companies

  • AELIX THERAPEUTICS

    Supported by Irsicaixa AIDS Research Institute, HIVACAT and ICREA.
    Entrepreneur: ICREA Research Professor Christian Brander.
    Born in November 2015.


    view details

    CLOSE

    AELIX THERAPEUTICS

    AELIX Therapeutics is a HIV vaccine development company focused on the development and clinical testing of HIV vaccine candidates.  Founded in December 2015, the company closed a first round of investment of 11.5 mio and has hired 4 employees with offices at the Parc Scientific in Barcelona. The company works closely with investigators at leading HIV research institutions in Barcelona (Hospital Clinc and Irsicaixa) and other centers abroad. These collaborations ensure direct patient access and excellent clinical and laboratory monitoring of future clinical trials.  A phase I clinical trial to test the safety of AELIX’s lead products is scheduled to start in the fall of 2016.  A proof-of concept phase II trial in HIV infected individuals is envisioned to be completed by the end of  2019.

    AELIX’s vaccine platform consists of a novel design of a HIV T cell immunogen sequence that is delivered by various vectors in HIV infected and uninfected individuals.  The immunogen design is based on detailed immune analyses in more than one thousand HIV infected individuals from 4 continents and covering geographic areas where different clades of HIV dominate.  Its design was completed within the HIVACAT program, the Catalan HIV vaccine program started in 2008.  The initial clinical application of this new vaccine approach is focused on its use as an HIV-specific immunotherapy in already HIV infected individuals.  The goal is to rejuvenate, re-educate or completely newly induce most effective CD4 and CD8 T cell responses to relatively conserved regions of the HIV proteome. Such responses are expected to act against a large portion of the global viral diversity and should allow infected individuals to avoid the need for life-long treatment with antiretroviral drugs.  Strategic partnerships will be developed to conduct future large-scale clinical trials and to possibly further improve viral control by including additional immune-based strategies and compounds acting on latent viral reservoirs.  With positive data in therapeutic proof-of-concept studies, AELIX will consider testing its lead candidate as a preventive vaccine as well.  

  • Ahead Terapautics S.L.

    Supported by the Institut Català de Nanociència i Nanotecnologia (ICN2) and ICREA.
    Entrepreneur: ICREA Research Professor Daniel Maspoch.
    Born in December 2017.


    view details

    CLOSE

    Ahead Terapautics S.L.

    Ahead Therapeutics SL was founded on December 2017 between the Germans Trias i Pujol Research Institute (IGTP), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA). The young biotech company is linked to the IGTP Immunology of Diabetes Research Group led by Dr Marta Vives-Pi and to the ICN2 Supramolecular Nanochemistry and Materials Group led by ICREA Research Prof. Daniel Maspoch, where researcher Dr Mary Cano is also based.

    The company was created to advance the development of therapies for autoimmune diseases and pursue their application in a clinical setting. It was established after the researchers generated and proved the efficacy of an immunotherapy approach for treating type 1 diabetes and multiple sclerosis based on nanotechnology. Specifically, the therapy uses liposomes to halt the self-destructive autoimmune response triggered by such diseases.

    The company aims to provide the financial and structural framework needed to take these results into the clinical arena and turn them into treatments for these and other autoimmune diseases, which are becoming more and more prevalent. Just weeks after it was founded, Ahead Therapeutics SL had received support from several investors. Apart from the seed capital, the company has already attracted 1.1 million euros in private funding.

  • BRAINGAZE

    Supported by the Universitat de Barcelona (UB) and ICREA.
    Entrepreneur: ICREA Research Professor Hans Supèr.
    Born in September 2013.


    view details

    CLOSE

    BRAINGAZE

    Braingaze SL, founded by Laslzo Bax and Hans Supèr, is a spin-off company from ICREA/UB. Braingaze offers a patented method to measure visual attention by analyzing minute eye movements of the observer. The method paves the way for the development of a novel and
    clean biomarker of attention for eye tracking applications. It operates with any commercial available binocular eye tracker device and can be incorporated into any existing eye tracker software package.

    Commercial applications

     Eye tracking is the process of measuring the point of eye gaze, i.e. where one is looking. In recent years, the increased sophistication and accessibility of eye tracking technologies have generated a great deal of interest in various business sectors. Existing applications include web usability, advertising, package design, user interfacing, and assistive technology. Emerging markets are automotive engineering, gaming industry, health care & diagnostics, production industry, and consumer electronics. Examples of applications being developed include mobile phones, lap-top integrated user interfaces, iPad and iPhone apps, gaming consoles and digital cameras.
    Eye position data is translated into the observers’ preference. But whether a message or product will be seen depends on the attention of the observer; not on eye position.
    Braingaze offers a software module that establishes if a subject actually perceived what he/she gazed at. Braingaze method drastically increases the value of the typical eye tracking maps produced up to now.

    Clinical applications

    Attention deficit hyperactivity disorder (ADHD) is a developmental disorder, and is the most commonly studied and diagnosed psychiatric disorder in children, affecting about 3% to 6% of children globally and diagnosed in about 2% to 16% of school aged children, and 3% in adults. The routine assessment of ADHD, which is based on questionnaires and developmental, physical and mental examination, has many flaws and is inaccurate. More importantly, while clear symptoms are present at 3 years of age, current diagnosis cannot be done before the age of 6 prohibiting early treatment, which is essential for preventing personal and social problems, and economical costs associated to ADHD.
    Braingaze offers a simple, fast, accurate tool to diagnose ADHD in children and adults. The biomarker of visual attention detects with high accuracy ADHD in children. As a result, diagnosis of ADHD can be more accurate, lower cost, less time consuming, observer-independent, earlier age diagnosis, and a much better communication of diagnosis fundamentals (by graphs rather than questionnaire responses being ranked). It also allows tracking progress of patient treatment. Braingaze intends to develop an exercise App allowing to pre-screen children for ADHD and to train children in their ability to focus attention and suppress distractive inputs.
    www.braingaze.com
     

  • Droplite Technologies

    Supported by the Institut de Ciències Fotòniques (ICFO) and ICREA.
    Entrepreneur: ICREA Research Professor Romain Quidant.
    Born in December 2018.


    view details

    CLOSE

    Droplite Technologies

    DROPLITE is developing a medical diagnostics device that allows a rapid and accurate way to detect diseases and other health conditions in both humans and animals. We introduce an on-site quantitative automated test based on immunoassay techniques that runs in less than 10min utilizing one single drop of whole blood (or others such as saliva or urine). We believe our technology can compete and eventually replace the expensive and time-consuming ELISA laboratory tests currently in used in hospitals and clinics.

    DROPLITE´s bio-sensing device is based on a reader + cartridge concept. A drop of blood of the patient is placed on an entry port of a small chip-cartridge, which is then introduced in a portable platform reader performing the detection and quantifying the concentration of the pathogen/molecule of interest present in the sample. The device, fully developed in house, is a combination of advanced microfluidics, customized chemistry, a proprietary optical detection system, electronics and signal processing.

    We are currently exploring applications in several different markets such as:

    (i) veterinary, regarding rapid detection of animal diseases,
    (ii) quantitative analysis of allergies,
    (iii) food safety,
    (iv) hormone monitoring and
    (v) early detection of infectious diseases.

  • EODYNE

    Supported by the Universitat Pompeu Fabra (UPF) and ICREA.
    Entrepreneur: ICREA Research Professor Paul Verschure.
    Born in November 2014.


    view details

    CLOSE

    EODYNE

    Eodyne Systems SL, a spin-off company from the research group SPECS (Synthetic, Perceptive, Emotive and Cognitive Systems) of the Center of Autonomous Systems and Neurorobotics (nras. upf.edu) at UPF, is launched to address one of the main health challenges our society is facing: functional recovery after brain damage which affects about 60 million people worldwide. Eodyne Systems SL will be commercializing a novel virtual reality based approach towards brain recovery and health, called the Rehabilitation Gaming System (RGS). RGS is based on the basic research performed by SPECS on the principles governing mind and brain and validated in collaboration with its clinical partners. After successfully treating about 400 patients at different stages of recovery after stroke and publishing the results in leading scientific journals and conferences, RGS is ready to be used by society. To achieve maximal distribution a commercial route is provided through the Eodyne Systems SL business strategy.

    The partners of Eodyne Systems SL are Professor Dr. Paul F.M.J. Verschure, director of SPECS Research Lab and the inventor of RGS,  Universitat Pompeu Fabra (UPF), the Catalan Institution for Research and Advanced Studies (ICREA) and Carmen Buisan, Senior project manager at SPECS.

    Eodyne’s flagship product, RGS, is a novel science-based solution for the integrated treatment of deficits that can result from stroke. RGS provides the global healthcare market with:

     

    * A low-cost tool for the neurorehabilitation of deficits in motor, affective, cognitive and linguistic capabilities due to brain damage

    * Applicability at all phases of treatment: acute and sub-acute (hospital or rehabilitation clinic) and chronic (home or health centre)

    * The active engagement of the patients in their rehabilitation following a personalized treatment approach

    * A system that empowers the patients and their social environment in the management of their own well being, customizing treatment to their means and lifestyle

    * An integrated system for remote treatment, diagnostics, monitoring and advise, allowing savings for patients and their relatives, primary healthcare providers, health centers and insurance companies

    * A life-long learning approach towards physical and mental health

    * A scientifically grounded state of the art ICT, artificial intelligence and virtual reality system that brings serious gaming to a qualitatively new level of deployment by integrating it with clinically validated methods and integrated solutions for diagnostic, monitoring and guidance.

    www.eodyne.com 

Pages